Foundation Medicine

Foundation Medicine has delivered over 80,000 reports for patients with hematologic malignancies, delivering insights to improve patient care. With our expertise in companion diagnostic development and the comprehensive FoundationOne?Heme* test, we help identify critical alterations such as translocations and fusions. Learn more by visiting us at booth 2604 or scheduling a meeting with our experts: https://spkl.io/6046fX1wi *LDT; Rx only; advanced cancer; doesn't guarantee treatment match.

Proud to support the lung cancer community this #LungCancerAwarenessMonth and beyond. Happy to help spread education and awareness around the work that ALK Positive Inc. is doing to help further research and better understand of ALK+ lung cancers.

November is a time dedicated to helping spread awareness and education around #MensHealth. From growing mustaches to participating in physical activity and moving for mental health, employees across Foundation Medicine have been participating in #Movember activities in support of this movement to change men’s health. Read through to see how some of our colleagues showed their “Mo.”

We’re proud to support education and awareness this #LungCancer Awareness Month. #DYK lung cancer is the leading cause of cancer death in the United States? Scroll through for more stats.

With the approval of new targeted therapies in the first-line setting for hormone receptor-positive, HER2-negative recurrent, metastatic #BreastCancer, the treatment landscape for advanced breast cancer patients is evolving. In a new Foundation Frontiers video, Dr. Mia Levy, Foundation Medicine’s chief medical officer and a practicing breast cancer oncologist, provides an update on the new #TargetedTherapy options for advanced breast cancer and explores the role of #ComprehensiveGenomicProfiling in treatment decision making. Watch on-demand now: https://spkl.io/6044fVfPM

Proud to announce that our blood-based, comprehensive genomic profiling (CGP) test has been approved by the FDA as a companion?diagnostic?for a targeted treatment for?patients with MET Exon 14 skipping alterations in non-small cell lung cancer. With this approval,?our blood-based CGP test is the first FDA-approved companion diagnostic to identify patients who may be eligible for?this?specific targeted treatment. Learn more:?https://lnkd.in/eAxGVDqF

Our team is excited to attend the International Society of Liquid Biopsy’s (ISLB) 6th Annual Congress of Liquid Biopsy. Visit us at booth 302 to learn how Foundation Medicine can support your team to provide genomic insights and precision medicine. Connect with a member of our team & schedule a time with us at the link here: https://spkl.io/6047fpF4H #ISLB24

Late last month, members of our team joined LUNGevity Foundation for their annual Breathe Deep Boston walk to kick off #LungCancer Awareness Month. It was a great morning supporting the lung cancer community and LUNGevity’s nationwide Breathe Deep TOGETHER event aimed at raising lung cancer awareness, the misconceptions around the disease and supporting those affected by it. More about LUNGevity at the link here: https://www.lungevity.org/

"As an oncologist who specializes in the treatment of breast cancer, I spend a good deal of time in the clinic thinking about the best care and treatment options for each of my patients. No patient is the same, and now, more than ever, patients with advanced disease have many personalized care paths to consider when facing a new diagnosis or progression of their cancer.” Hear more from Chief Medical Officer, Dr. Mia Levy in a new blog on #breastcancer: https://spkl.io/6044fpmPQ